دورية أكاديمية
أعرض في EDS

Uterine washings as a novel method for early detection of ovarian cancer: Trials and tribulations.

التفاصيل البيبلوغرافية
العنوان: Uterine washings as a novel method for early detection of ovarian cancer: Trials and tribulations.
المؤلفون: Sia TY; Department of Surgery, Memorial Sloan Kettering Cancer Center, New York, NY, USA., Yaari Z; School of Pharmacy, Department of Medicine, Hebrew University of Jerusalem, Israel., Feiner R; Department of Laboratory Medicine, Memorial Sloan Kettering Cancer Center, New York, NY, USA., Smith E; Department of Surgery, Memorial Sloan Kettering Cancer Center, New York, NY, USA., Da Cruz Paula A; i3S Instituto de Investigação e Inovação em Saúde, Porto, Portugal.; Department of Pathology and Laboratory Medicine, Memorial Sloan Kettering Cancer Center, New York, NY, USA., Selenica P; Department of Pathology and Laboratory Medicine, Memorial Sloan Kettering Cancer Center, New York, NY, USA., Doddi S; Department of Laboratory Medicine, Memorial Sloan Kettering Cancer Center, New York, NY, USA., Chi DS; Department of Surgery, Memorial Sloan Kettering Cancer Center, New York, NY, USA.; Department of OB/GYN, Weill Cornell Medical College, New York, NY, USA., Abu-Rustum NR; Department of Surgery, Memorial Sloan Kettering Cancer Center, New York, NY, USA.; Department of OB/GYN, Weill Cornell Medical College, New York, NY, USA., Levine DA; Merck Research Laboratories, Rahway, NJ, USA., Weigelt B; Department of Pathology and Laboratory Medicine, Memorial Sloan Kettering Cancer Center, New York, NY, USA., Fleisher M; Department of Laboratory Medicine, Memorial Sloan Kettering Cancer Center, New York, NY, USA., Ramanathan LV; Department of Laboratory Medicine, Memorial Sloan Kettering Cancer Center, New York, NY, USA., Heller DA; Molecular Pharmacology Program, Memorial Sloan Kettering Cancer Center, New York, NY, USA.; Department of Pharmacology, Weill Cornell Medical College, Cornell University, New York, NY, USA., Long Roche K; Department of Surgery, Memorial Sloan Kettering Cancer Center, New York, NY, USA.; Department of OB/GYN, Weill Cornell Medical College, New York, NY, USA.
المصدر: Gynecologic oncology reports [Gynecol Oncol Rep] 2024 Feb 03; Vol. 51, pp. 101330. Date of Electronic Publication: 2024 Feb 03 (Print Publication: 2024).
نوع المنشور: Journal Article
اللغة: English
بيانات الدورية: Publisher: Elsevier Country of Publication: Netherlands NLM ID: 101652231 Publication Model: eCollection Cited Medium: Print ISSN: 2352-5789 (Print) Linking ISSN: 23525789 NLM ISO Abbreviation: Gynecol Oncol Rep Subsets: PubMed not MEDLINE
أسماء مطبوعة: Original Publication: Amsterdam : Elsevier, [2013]-
مستخلص: Given the tubal origin of high-grade serous ovarian cancer (HGSC), we sought to investigate intrauterine lavage (IUL) as a novel method of biomarker detection. IUL and serum samples were collected from patients with HGSC or benign pathology. Although CA-125 and HE4 concentrations were significantly higher in IUL samples compared to serum, they were similar between IUL samples from patients with HGSC vs benign conditions. In contrast, CA-125 and HE4 serum concentrations differed between HGSC and benign pathology ( P  =.002 for both). IUL and tumor samples from patients with HGSC were subjected to targeted panel sequencing and droplet digital PCR (ddPCR). Tumor mutations were found in 75 % of matched IUL samples. Serum CA-125 and HE4 biomarker levels allowed for better differentiation of HGSC and benign pathology compared to IUL samples. We believe using IUL for early detection of HGSC requires optimization, and current strategies should focus on prevention until early detection strategies improve.
Competing Interests: The authors declare the following financial interests/personal relationships which may be considered as potential competing interests: D.A.H. is a co-founder and officer with equity interest of Lime Therapeutics Inc., co-founder with equity interest of Selectin Therapeutics Inc. and Resident Diagnostics, Inc., and a member of the scientific advisory boards of Concarlo Therapeutics Inc., Nanorobotics Inc., and Mediphage Bioceuticals Inc. B.W. reports research funding by Repare Therapeutics, outside of the submitted work. E.S. reports honoraria from Dilon Technologies, Inc. D.A.L. is a full-time employee of Merck & Co., Inc. (Rahway, NJ, USA) and a co-founder with equity interest of Resident Diagnostics, Inc. N.A.R. reports grant funding from GRAIL paid to the institution. D.S.C. reports personal fees from Apyx Medical, Verthermia Inc., Biom 'Up, and AstraZeneca, as well as recent or current stock/options ownership of Apyx Medical, Verthemia, Intuitive Surgical, Inc., TransEnterix, Inc., Doximity, Moderna, and BioNTech SE. K.L.R. reports travel support from Intuitive Surgical. T.Y.S and M.F. have no conflicts of interest to report.
(© 2024 The Authors. Published by Elsevier Inc.)
References: Int J Gynecol Cancer. 2018 Nov;28(9):1692-1698. (PMID: 30376484)
Lancet. 2021 Jun 5;397(10290):2182-2193. (PMID: 33991479)
Nature. 2011 Jun 29;474(7353):609-15. (PMID: 21720365)
Obstet Gynecol. 2014 Nov;124(5):881-885. (PMID: 25437714)
J Clin Oncol. 2015 Dec 20;33(36):4293-300. (PMID: 26552420)
Nat Biomed Eng. 2022 Mar;6(3):267-275. (PMID: 35301449)
Nat Commun. 2019 Nov 26;10(1):5367. (PMID: 31772167)
JAMA Oncol. 2015 Nov;1(8):1128-32. (PMID: 26181193)
J Pathol. 2018 Nov;246(3):344-351. (PMID: 30043522)
Sci Adv. 2021 Nov 19;7(47):eabj0852. (PMID: 34797711)
JAMA Netw Open. 2020 Jul 1;3(7):e207566. (PMID: 32609349)
Cancer Res Commun. 2022 Oct;2(10):1282-1292. (PMID: 36311816)
BJOG. 2007 Dec;114(12):1500-9. (PMID: 17903229)
Sci Transl Med. 2018 Mar 21;10(433):. (PMID: 29563323)
معلومات مُعتمدة: P30 CA008748 United States CA NCI NIH HHS
فهرسة مساهمة: Keywords: Early detection; Intrauterine lavage; Ovarian cancer
تواريخ الأحداث: Date Created: 20240215 Latest Revision: 20240409
رمز التحديث: 20240409
مُعرف محوري في PubMed: PMC10865230
DOI: 10.1016/j.gore.2024.101330
PMID: 38356691
قاعدة البيانات: MEDLINE
الوصف
تدمد:2352-5789
DOI:10.1016/j.gore.2024.101330